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RAS  mutation  analysis  is an  important  companion  diagnostic  test.  Treatment  of  colorectal  cancer  with
anti-Epidermal  Growth  Factor  Receptor  (EGFR)  therapy  requires  demonstration  of RAS mutation  status
(both  KRAS  and  NRAS),  and  it is  good  practice  to include  BRAF.  In Non-Small  Cell  Lung Cancer  (NSCLC)
and  melanoma,  assessment  of  RAS  mutation  status  can  be helpful  in triaging  patient  samples  for more
extensive  testing.  This  mini-review  will discuss  the  role  of  PCR methods  in providing  rapid  diagnostic
information  for cancer  patients.eywords:
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. Introduction
The rat sarcoma viral oncogene homolog (RAS) family of mem-
rane associated GTPase signalling molecules are involved in
athways that mediate cell growth. Many of these pathways inter-
ct, and different cell types use them differently, so the effects
f activation by growth factors or mutation in key genes differ
etween cell and cancer types. The human RAS family consists of
hree genes Harvey RAS (HRAS), Kirsten RAS (KRAS), and Neurob-
astoma RAS (NRAS) [1,2].
The clinical need for KRAS mutation testing is largely related to
he use of anti-EGFR antibody therapy for patients with advanced
olorectal cancer [3]. Virtually all colorectal cancers express EGFR,
ut few respond to treatment directed against the receptor
ecause they have downstream activating mutations in signalling
olecules including KRAS. It has now been shown that NRAS muta-
ions in patients with colorectal cancer have the same effect. There
s also increasing evidence from systematic reviews that B-Raf
roto-oncogene (BRAF) mutations, which confer a worse progno-
is, also confer a degree of resistance [4], and strong suspicion that
IK3CA mutations are also important [4]. This backs up reports
rom series of patients treated with anti-EGFR molecules [5], and
n vitro data using cell lines, in which activation of downstream
ignalling leads to resistance to anti-EGFR molecules [6]. It also has
ecently become apparent that resistance may  occur during treat-
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genes [7]. While the pharmaceutical licenses for anti-EGFR anti-
body therapeutics (e.g. cetuximab, panitumumab) granted by the
Federal Drug Administration, and in the Europe by the European
Medicines Agency (EMA), require the use of KRAS and NRAS muta-
tion testing to exclude mutations before their use, this is not yet a
requirement for BRAF or PIK3CA [8,9].
KRAS is of importance in other tumour types, and knowledge of
KRAS mutational status can be helpful to guide further investiga-
tions. For instance, if a lung cancer has a KRAS mutation, there is
little point in sending off biopsy material for Anaplastic lymphoma
kinase (ALK) fusion gene testing, as the KRAS mutation will be the
driver mutation and ALK will almost certainly be wild-type [10].
As yet, there are few therapeutic options for patients with KRAS
mutated tumours, but this is likely to change, and knowledge of
the KRAS mutational status of many tumours will then be of greater
signiﬁcance [8].
The activation of molecules such as KRAS by mutation requires
conformational changes at the protein level, so not all mutations in
KRAS are activating and able to drive carcinogenesis [1,9]. There are
therefore ‘hotspots’ within KRAS that allow testing to be done with-
out sequencing the entire gene. The American Society of Clinical
Oncology (ASCO) have recently published guidance recommend-
ing testing of codons 12 and 13 of exon 2; 59 and 61 of exon 3;
and 117 and 146 of exon 4 (known as “expanded” or “extended”
RAS mutation testing, Table 1) [9]. This list is now widely used,
but not all commercially available tests cover these codons. The
corresponding mutations covered in guidance for testing laborato-
 license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table  1
Mutations in KRAS and NRAS for which testing should be performed in patients with
colorectal cancer. The exons and codons listed are common to both KRAS and NRAS.
Exon Codon Example Mutations
2 12 G12C (c.34G > T)
G12R (c.34G > C)
G12S (c.34G > A)
G12A (c.35G > C)
G12D (c.35G > A)
G12V (c.35G > T)
13  G13D (c.38G > A)
3  59 A59E (c.176C > A)
A59G (c.176C > G)
A59T (c.175G > A)
61  Q61K (c.181C > A)
Q61L (c.182A > T)
Q61R (c.182A > G)
Q61H (c.183A > C)
Q61H (c.183A > T)
4 117 K117N (c.351A > C)
146 A146P (c.436G > C)
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ies are listed in Table 1, with example mutations. Most external
uality assurance (EQA) schemes (e.g. UKNEQAS, Edinburgh, UK
nd European Society of Pathology EQA scheme) require reports
o be submitted to their molecular pathology schemes, based on
rug licence information (see http://www.ukneqas-molgen.org.uk/
olecular-pathology and http://kras.eqascheme.org) [11,12].
. PCR tests for KRAS mutation
Tests for KRAS mutations usually employ polymerase chain
eaction (PCR). Modern, particularly automated, PCR methods
re relatively simple to perform and provide rapid diagnosis at
ood sensitivity. It is perfectly possible to go from formalin-ﬁxed
arafﬁn-embedded (FFPE) tumour sample to result in a few hours,
ather than a few days. There are a large number of methods avail-
ble, suited to small and large laboratories. Most manufacturers
f PCR machines used clinically have options for RAS analysis. The
ommonest commercial options are well validated, widely used,
nd as shown in Table 2, in three cases, approved by the US Fed-
ral Drug Administration (FDA). The Therascreen (Qiagen) offering
s based on the ampliﬁcation refractory mutation system (ARMS)
echnology [13,14], and is widely used. The Cobas (Roche) assay
ses a CE-IVD marked TaqMelt PCR assay designed to detect the
resence of 19 KRAS mutations in codons 12, 13, and 61 from just
00 ng of DNA extracted from FFPE samples [15]. Comparison the
wo assays have shown excellent concordance [16], but it should
e noted that the cobas assay has a more extensive coverage. The
ost recently approved assay, the Idylla system from Biocartis,
ntegrates DNA extraction and multiplex PCR in a simple-to-use
assette, and also has wide coverage (www.biocartis.com). There
re presently few publications using this method, but its ﬁrst offer-
ng for BRAF mutation has performed well [17–19].
The limit of detection (LoD) is given by most manufacturers as
he lowest percentage mutant DNA detectable against background
ild-type DNA. The best assays achieve 1%, but most manufacturers
uote <5% in their literature. This means that the lower the per-
entage of neoplastic cells present, the higher the effective limit of
etection. Manufacturers and users generally quote 10% neoplas-
ic cells as a threshold below which it is not worth testing, as the
ffective limit of detection for mutations in such clinical material
ill be between 10% and 50% at that point [11]. It is important
hat this is taken into account when reporting the results of such
ests, and close cooperation between histopathology and molecular
athology is essential [11]. Quantiﬁcation 8 (2016) 29–32
Laboratory-developed tests (also known as in-house assays) for
RAS mutation analysis (Table 3) are widely used in Europe and by
clinical laboratories operating under the The Clinical Laboratory
Improvement Amendments of 1988 (CLIA) regulations in the USA,
as well as in research. The onus is on the laboratory to validate the
test to ensure that the results are reliable [11]. Many of reagents are
sold as research use only (RUO). The results from external quality
assurance schemes (e.g. UKNEQAS, ESP) suggest that in well-run,
suitably accredited laboratories, such tests are as safe and effective
as those with approval for clinical use [11].
One advantage of developing tests locally is that there are a
large number of different methods to choose from and it is pos-
sible to design tests to meet local requirements. Most methods
use some of PCR enrichment to ensure low levels of detection of
mutant DNA against a background of wild-type DNA. The castPCR
(ThermoFisher) method can be used in both 96 well plates and Taq-
Man  Arrays and shows good concordance with both Therascreen
(Qiagen) and IonTorrent NGS [20,21]. PCR clamping incorporates
peptide nucleic acids (PNAs) or locked nucleic acids (LNAs) to
reduce the ampliﬁcation of mutant DNA [22–25], while high
resolution melt (HRM) methods use close control of annealing tem-
peratures to favour ampliﬁcation of mutant DNA[26,27]. HRM can
also be used as a prior to sequencing to increase sensitivity [28,29].
3. Factors affecting assay choice
Guidance for molecular pathology [11] covers most of the
requirements for test implementation and should be consulted
before starting. One of the key considerations for assay choice is
the number of samples needing testing. There is a trade-off between
the cost per assay and the number performed. Efﬁciencies of scale
mean that for many laboratories, it is better to send away rarely
required tests, and to concentrate on those that are commonly
requested. Turnaround time for patients, from biopsy to action on
the result of a test, tends to be slower for those samples sent away,
and if the result is required quickly, this may  mean that a labora-
tory has to take on testing it would otherwise prefer to send away.
Timeliness of diagnostic reporting is an essential component of
the decision, and should be considered by multidisciplinary teams
(tumour boards) considering setting up such services.
Laboratory facilities are a further consideration. Space is rarely
an issue as PCR machines are all of bench-top type, but most molec-
ular pathology methods require considerable expertise both to
extract DNA from samples, to perform the tests, and to interpret
the results.
Both NGS and PCR have advantages and disadvantages. While
sequencing can look at entire genes, most PCR methods and
targeted sequencing methods employ primers and probes that
look for deﬁned mutations. This makes them less comprehensive,
but makes interpretation easier. Many next targeted generation
sequencing (NGS) depend on PCR for library preparation and some
can be thought of as a post-PCR methods (e.g. IonTorrent Ampliseq,
ThermoFisher, Paisley, UK) [30,31]. Targeted NGS uses the applica-
tion of highly parallel sequencing methods to analyse vast numbers
of overlapping PCR products to cover whole exons or even genes.
This allows even rare mutations to be detected, but at a cost in terms
of time, complexity of analysis and interpretation, and economics
[11].
Whatever the analytical method used, DNA needs to be
extracted from formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue
for assay. It is important to ensure that tissue is ﬁxed promptly,
but not overﬁxed (i.e. <72 h), and that neutral buffered formalin
is used [11]. Tissue processing should not use high temperatures
(i.e. <65 ◦C) to optimise DNA recovery [32]. DNA extraction can
be manual, using one of several systems from companies such as
I.A. Cree / Biomolecular Detection and Quantiﬁcation 8 (2016) 29–32 31
Table  2
Currently available PCR methods (FDA approved) for FFPE tissue determination of KRAS mutation status. LoD, Limit of Detection http://www.fda.gov/MedicalDevices/
ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
Features Therascreen (Qiagen) Cobas (Roche) Idylla (Biocartis)
Starting material DNA DNA FFPE section
Coverage Codons 12 and 13 Codons 12, 13, 61 Codons 12, 13, 59, 61, 117, 146
Analytical Sensitivity (LoD) <5% <5% 5%
Neoplastic cell% limit 10% 10% NA
Duration of test <8 h <8 h 2 h
Reagents Liquid Liquid Cassette
Results Manual Automated Automated
Table 3
Examples of currently available PCR methods using RUO reagents.
Features CastPCR (ThermoFisher) PCR Clamping High Resolution Melt
Starting material DNA DNA DNA
Coverage Depends on plate layout Depends on primerschosen Depends on primers chosen
Analytical Sensitivity (LoD) <5% <5% <5%
Neoplastic cell% limit 10% 10% 10%
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Results  Manual 
lonTech, ThermoFisher and Qiagen, or automated. We  have used
he Maxwell (Promega) system for a number of years, with good
esults, but other systems are coming onto the market, several of
hich use standard laboratory robots [20,32]. One difference is
hat while all automated systems tend to use enzymatic release
nd magnetic bead based extraction, manual systems are often
lter-based. DNA can also be released from FFPE by focussed ultra-
ound (Covaris, http://covarisinc.com/products/ffpe-extraction/), a
ethod that has found application in the extraction of DNA for
equencing [33]. Completely automated cassette-based systems,
hich do their own extraction, are a rarity, but the Idylla (Biocartis)
s an example [17–19].
Commercial assays are designed to cope with the demands of
utation detection in the fragmented DNA recovered from FFPE
amples. Most of the DNA recovered will be less than 150 base
airs in length, and this is therefore the maximum length of the
CR products that should be used in KRAS and other gene muta-
ion assays [11]. Shorter amplicon sizes can improve sensitivity.
he same issue applies to NGS, and causes problems for whole
enome sequencing in particular. The alternative is to use fresh tis-
ue, but that may  compromise the histopathological diagnosis and
s not recommended. The histopathologist should assess the sam-
le, estimate the percentage of neoplastic cells present, and mark
reas for assay. Many laboratories use sections scraped from glass
lides, while others use rolled sections. For larger biopsies or surgi-
al resections, we use disposable 1 mm punches to take a core from
he block corresponding to areas of tumour with >50% neoplastic
ells marked on the diagnostic H&E slide [20].
Interpretation of the results of KRAS mutation analysis, or indeed
ny other molecular assay, requires knowledge of the assay, and
he pre-analytical issues, but also an appreciation of the likely clin-
cal consequences of the results and the drugs used. In Europe, the
athologist signing the report is responsible for its accuracy, even if
he assay is performed in another laboratory. The ease with which
esults can be assessed and reported varies between systems, and
ew interface directly with Laboratory Information Management
ystems (LIMS). In this respect, PCR and sequencing technolo-
ies lag behind those used in automated blood sciences labs, or
istopathology. The consequence is that results need to be typed
nto LIMS systems manually, with the inherent risks of sample
isidentiﬁcation and typographical errors in mutations. Mutations
hould be reported using Human Genome Variation Society (HGVS)
omenclature (http://www.hgvs.org/mutnomen/) and an interpre-3–4 h 3–4 h
Liquid Liquid
Manual Manual
tation given which is understandable to the clinician who  must act
on it, while allowing a pathologist to understand what test has been
done and its limitations.
The effect of all of these choices on service provision can be
modelled using the Cancer Molecular Diagnostic Implementation
Planning and Commissioning Toolkit
(CMD-ImPACT) tool which is freely available from the UK Royal
College of Pathologists (RCPath) website (https://www.rcpath.org/
cmd-impact.html). Guidance on how to set up and run a molecular
pathology laboratory is available from several sources, particularly
College of American Pathologists (http://www.cap.org/), the Asso-
ciation for Molecular Pathology (http://www.amp.org), and the
European Society of Pathology [11].
4. Future directions
There is little doubt that more drugs will become available, and
the need for KRAS testing will increase. However, the number of tar-
gets requiring interrogation is also increasing, and KRAS is but one
of these. There is therefore an increasing requirement to test more
than one gene in a given cancer, and the use of panel testing is likely
to increase accordingly. Sequencing panels such as the IonTorrent
colorectal and lung cancer 22 gene panel are comprehensive, but
NGS requires considerable expertise and remains more expensive
than PCR. We have recently developed an in-house Taqman array
panel for commonly requested mutations in RAS (KRAS and NRAS),
EGFR, and BRAF [21]. We are able to extract DNA from 7 samples
and run the plate within a few hours with around 15 min hands-
on time, allowing us to run a plate twice week giving patients a
maximum turnaround time of 3–4 days. Those samples in which
no mutation is found, or where there is a clinical requirement for
additional information, can then submitted for further testing by
NGS or FISH.
Finally, the use of liquid biopsy is rapidly increasing, and has
entered practice in some centres to augment tissue based test-
ing [34]. Circulating free DNA (cfDNA) should be extracted from
plasma rather than serum. Although cfDNA levels in serum are
higher, this reﬂects DNA from leukocytes due to clotting, and there
is consequent dilution of circulating tumour-derived DNA (ctDNA).
Plasma cfDNA is fragmented and product sizes less than 150 bp
are required. Methods with greatest sensitivity include BEAMing
and digital droplet PCR, but IonTorrent sequencing is also able
to reach similar sensitivity (Laurent-Puig, personal communica-
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ion). A number of new assays are in development and this ﬁeld
s developing rapidly. To date, there have been insufﬁcient clinical
alidation studies reported. These are a requirement if these meth-
ds are to be used in the clinic, where they could certainly meet
 need for patients on treatment who require monitoring, and in
atients where biopsy material is not available.
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